Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Figures corrected NBB
Corrected annual account filed for 2022.
Financials
Financial year 2025
ODYSSEA PHARMA from Grâce-Hollogne, company number BE0892121272, closed financial year 2025 with a result of € 35.9 million after tax. For that financial year ODYSSEA PHARMA recorded revenue of € 76.2 million and equity of € 76.4 million. Compared with financial year 2024, the result moved from € 11.2 million to € 35.9 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 3, 2026.
€ 76.4 million
▲ 88% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 35.9 million
▲ 221% vs 2024
Profit after tax over the fiscal year.
€ 0
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -13.8 million.
People and assets in 2025
62.4
▲ 3.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 6.6 million
▲ 12% vs 2024
€ 105,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 531,325
▲ 293% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 11.5 million
▲ 32% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 162 days on average.
€ 3.1 million
▲ 116% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 41,899,177 | € 35,319,082 | € 43,391,996 | € 76,159,559 | ▲ 76% |
| Profit after taxes | € 15,989,584 | € -3,404,109 | € 11,180,686 | € 35,850,240 | ▲ 221% |
| Equity | € 32,761,679 | € 29,357,570 | € 40,538,256 | € 76,388,496 | ▲ 88% |
| Total debts | € 7,349,772 | € 23,125,214 | € 10,121,177 | € 14,614,370 | ▲ 44% |
| Cash | € 1,162,784 | € 120,793 | € 0 | € 0 | |
| Land & buildings | € 541,626 | € 4,701,034 | € 7,545,193 | € 7,718,803 | ▲ 2% |
| Retained profit | € -57,384,657 | € -60,788,766 | € -49,608,080 | € -13,757,840 | ▲ € 35.9 million |
| Bank debt | € 460,567 | € 0 | € 0 | € 0 | |
| Balance sheet total | € 40,111,451 | € 52,482,784 | € 50,659,433 | € 91,002,866 | ▲ 80% |
| Employees (FTE) | 67.2 | 61.6 | 59 | 62.4 | ▲ 3.4 |
Key figures of ODYSSEA PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ODYSSEA PHARMA?
What happened at ODYSSEA PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 35.9 million (▲ 221% vs 2024). Source: NBB ↗
- David Brésart became a director. NBB
- Maurice Mulders became a director. NBB
- New establishment in Grâce-Hollogne. KBO
- Start of the company according to the CBE. KBO
In short
From € 16 million profit in 2022 to € 35.9 million profit in 2025.
Paid € 5.6 million in corporate taxes since 2022.
Best year ever: 2025, with € 35.9 million profit.
Pays suppliers within 162 days on average.
A new publication or filing at ODYSSEA PHARMA? We notify you, reason included.
Follow ODYSSEA PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind ODYSSEA PHARMA are David Brésart and Maurice Mulders.
Directors
According to the 2025 annual accounts
David Brésart
Director
since 2025
Maurice Mulders
Director
since 2016
Establishments
Establishment units
Physical locations of this company
Rue du Travail 16
4460 Grâce-Hollogne
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0892.121.272
- VAT number
- BE 0892.121.272
- Registered office
- Rue du Travail 16, 4460 Grâce-Hollogne
- Names & denominations
- ODYSSEA PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 18 September 2007
- Peppol
- Active · Active since 27 Nov 2025
- Activities · NACE
Vervaardiging van geneesmiddelen